Non-coding RNAs in lung cancer: emerging regulators of angiogenesis

Lung cancer is the second cancer and the leading cause of tumor-related mortality worldwide. Angiogenesis is a crucial hallmark of cancer development and a promising target in lung cancer. However, the anti-angiogenic drugs currently used in the clinic do not achieve long-term efficacy and are accom...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 20; no. 1; pp. 1 - 11
Main Authors Liao, Yajie, Wu, Xudong, Wu, Mengyu, Fang, Yuan, Li, Jie, Tang, Weiqiang
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 02.08.2022
BioMed Central
BMC
Subjects
Angiogenesis
Antiangiogenic agents
Binding sites
Cancer therapies
Care and treatment
Cell growth
Development and progression
Drug development
Drugs
Fibroblasts
Gene expression
Genetic aspects
Health aspects
Hypoxia
Lung cancer
Mechanisms
Medical prognosis
Metastasis
MicroRNAs
Neovascularization
Non-coding RNA
Non-coding RNAs
Physiology
Review
RNA
Tumors
Vascular endothelial growth factor
China
Online AccessGet full text

Cover

More Information
Summary:Lung cancer is the second cancer and the leading cause of tumor-related mortality worldwide. Angiogenesis is a crucial hallmark of cancer development and a promising target in lung cancer. However, the anti-angiogenic drugs currently used in the clinic do not achieve long-term efficacy and are accompanied by severe adverse reactions. Therefore, the development of novel anti-angiogenic therapeutic approaches for lung cancer is urgently needed. Non-coding RNAs (ncRNAs) participate in multiple biological processes in cancers, including tumor angiogenesis. Many studies have demonstrated that ncRNAs play crucial roles in tumor angiogenesis. This review discusses the regulatory functions of different ncRNAs in lung cancer angiogenesis, focusing on the downstream targets and signaling pathways regulated by these ncRNAs. Additionally, given the recent trend towards utilizing ncRNAs as cancer therapeutics, we also discuss the tremendous potential applications of ncRNAs as biomarkers or novel anti-angiogenic tools in lung cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1479-5876
1479-5876
DOI:10.1186/s12967-022-03553-x